Results 141 to 150 of about 26,593 (244)

Focal Spot, Fall/Winter 2000 [PDF]

, 2000
https://digitalcommons.wustl.edu/focal_spot_archives/1086/thumbnail ...

core   +1 more source

Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions

MedComm, Volume 7, Issue 4, April 2026.
Antibody–drug conjugates integrate antibody targeting with potent cytotoxic payloads to enable precision cancer therapy. Their clinical performance depends on coordinated optimization of engineering design, tumor antigen biology, and treatment strategy. Lessons from uro‐oncological malignancies illustrate how ADCs can be effectively developed, combined,
Bisheng Cheng, Lanqi Gong, Zongwei Wang, Peidan Peng, Kewei Xu, Hai Huang, Peng Wu   +6 more
wiley   +1 more source

Targeted Therapies for Each Subtype of Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This review systematically summarizes the advances in targeted therapies for the three major molecular subtypes of breast cancer (BC), highlighting key strategies, agents, and clinical progress to guide personalized treatment. HR‐positive (luminal) BC: Dominated by estrogen receptor (ER) signaling, with endocrine therapies as the cornerstone—including ...
Aiyu Liu, Puchao Peng, Yeke Zhu, Qiuwen Fei, Weiwei Liu, Shizhen Zhang   +5 more
wiley   +1 more source

Uptake and Binding of At‐211 Into K‐ and Cs‐Derivatives of Alpha‐Zirconium Phosphate Nanoplatelets for Use as a Targeted Alpha Therapy Delivery Platform

Small Science, Volume 6, Issue 4, April 2026.
Intercalation of At‐211 between the layers of K‐ or Cs‐zirconium phosphate. The ion exchange behavior of K‐ and Cs‐derivatives of α‐zirconium phosphate, A‐ZrP, with the targeted alpha therapy (TAT) radionuclide 211At, as At+ and AtO+, has been investigated. The K‐ZrP shows strong affinity for both At+ and AtO+, ≥99% uptake.
B. D. Imansha Madhushan, Adrianna L. Orsi, Jehan S. Perera, Jennifer M. Pyles, Christine C. Lawrence, Marcus Le, Gabriel C. Tabacaru, Shayden R. Fritz, Lauren A. McIntosh, Sherry J. Yennello, Jonathan D. Burns   +10 more
wiley   +1 more source

Cutting‐edge advances in bicyclic peptide‐based radiotracers for cancer imaging and theranostics

VIEW, Volume 7, Issue 2, April 2026.
Bicyclic peptides, a burgeoning subset of bicyclic macrocycles, are characterized by two loops stabilized through three linkages of the central chemical scaffolds. As an immense potential platform for radiotracers development, bicyclic peptide‐based radiotracers have yielded encouraging results in preclinical and clinical trial studies.
Hengyi Ou, Xiaobo Wang, Fei Kang
wiley   +1 more source

Enhancing Diagnostic Pathways for Bronchopulmonary Neuroendocrine Tumors: Assessment of the South Wales Neuroendocrine Tumor Service Transformation

Thoracic Cancer, Volume 17, Issue 8, April 2026.
Implementation of a dedicated neuroendocrine cancer service in South Wales significantly shortened diagnostic and treatment timelines for bronchopulmonary NETs, demonstrating the benefits of coordinated specialist input. ABSTRACT Background Bronchopulmonary neuroendocrine tumors (bpNETs) are uncommon lung neoplasms posing significant diagnostic and ...
Arouba Imtiaz, Oliver Burbidge, Mat Jones, Robin Ghosal, Janardhan Navaratnam, Craig Dyer, Helen E. Davies, Mohid S. Khan   +7 more
wiley   +1 more source

Targeted radionuclide therapy [PDF]

Journal of Labelled Compounds and Radiopharmaceuticals, 2007
openaire   +1 more source

Post‐Therapeutic Dosimetry of Metastatic Castration‐Resistant Prostate Cancer With 177Lu‐PSMA: Experiences From Two University‐Based Hospitals in Thailand

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 199-206, April 2026.
ABSTRACT Objective 177Lu‐PSMA radioligand therapy (RLT) is increasingly used to treat metastatic castration‐resistant prostate cancer (mCRPC). Posttreatment dosimetry is essential for assessing normal organ absorbed doses. Therefore, this study aims to evaluate normal organs dosimetry in mCRPC patients undergoing 177Lu‐PSMA‐RLT from two university ...
Onnicha Pattanawong, Putthiporn Charoenphun, Wichana Chamroonrat, Thonnapong Thongpraparn, Nucharee Poon‐iad, Benjapa Khiewvan, Krisanat Chuamsaamarkkee   +6 more
wiley   +1 more source

Enhancing diabetic foot osteomyelitis diagnosis with metagenomics next‐generation sequencing, proof of concept

Diabetic Medicine, Volume 43, Issue 4, April 2026.
The use of mNGS with the MinION tool clearly provides a significant advantage compared to routine culture by identifying a higher diversity of pathogens in diabetic foot osteomyelitis. It also highlights the value of this method in clinical decision making, despite the technical challenges inherent in metagenomic sequencing.
Madjid Morsli, Chloé Magnan, Florian Salipante, Adeline Dubois, Sophie Schuldiner, Nicolas Cellier, Albert Sotto, Jean‐Philippe Lavigne, Catherine Dunyach‐Remy   +8 more
wiley   +1 more source

Endoscopic Ultrasound for the Management of Pancreatic Neuroendocrine Tumors: Diagnosis, Treatment, and Future Perspectives

Journal of Gastroenterology and Hepatology, Volume 41, Issue 4, Page 1173-1190, April 2026.
ABSTRACT Pancreatic neuroendocrine tumors (PanNETs) are increasingly diagnosed, reflecting greater clinical awareness, improved imaging, and revised classification. This review summarizes evidence on epidemiology, diagnostic workup, and endoscopic ultrasound (EUS)–guided management of PanNETs, encompassing diagnostic evaluation, tissue acquisition, and
Angelo Bruni, David Meacci, Roberto Falbo, Marco Fichera, Francesco Poggioli, Riccardo Casadei, Claudio Ricci, Leonardo Henry Eusebi   +7 more
wiley   +1 more source